S. Burza, S. L. Croft, and M. Boelaert, Leishmaniasis. Lancet, vol.392, pp.951-970, 2018.

P. Buscher, G. Cecchi, V. Jamonneau, and G. Priotto, Human African trypanosomiasis, Lancet, vol.2017, pp.2397-2409, 10110.
URL : https://hal.archives-ouvertes.fr/hal-02322417

J. A. Pe?ez-molina, I. Molina, and . Chagas-disease, Lancet, vol.391, pp.82-94, 2018.

G. Bilbe, Overcoming neglect of kinetoplastid diseases, Science, vol.348, issue.6238, pp.974-976, 2015.

D. G. Silva, J. R. Gillespie, R. M. Ranade, Z. M. Herbst, U. T. Nguyen et al., New class of antitrypanosomal agents based on imidazopyridines, ACS Med. Chem. Lett, vol.2017, issue.7, pp.766-770

J. Konstantinovic, M. Videnovic, S. Orsini, K. Bogojevic, S. D'alessandro et al., Novel aminoquinoline derivatives significantly reduce parasite load in Leishmania infantum infected mice, ACS Med. Chem. Lett, vol.2018, issue.7, pp.629-634

W. Devine, S. M. Thomas, J. Erath, K. A. Bachovchin, P. J. Lee et al., Antiparasitic lead discovery: toward optimization of a chemotype with activity against multiple protozoan parasites, ACS Med. Chem. Lett, vol.2017, issue.3, pp.350-354

F. Chappuis, Oral fexinidazole for human African trypanosomiasis, Lancet, vol.391, pp.100-102, 2018.

S. Patterson, S. Wyllie, S. Norval, L. Stojanovski, F. R. Simeons et al., The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis, vol.5, 2016.

A. H. Fairlamb and S. Patterson, Current and future prospects of nitro-compounds as drugs for trypanosomiasis and leishmaniasis, Curr. Med. Chem

A. A. Voak, V. Gobalakrishnapillai, K. Seifert, E. Balczo, L. Hu et al., An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs, J. Biol. Chem, issue.40, pp.28466-28476, 2013.

S. Wyllie, S. Patterson, L. Stojanovski, F. R. Simeons, S. Norval et al., The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis, Sci. Transl. Med, vol.2012, issue.119, pp.119-120

S. Wyllie, S. Patterson, and A. H. Fairlamb, Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation, Antimicrob. Agents Chemother, vol.57, issue.2, pp.901-906, 2013.

S. Wyllie, A. J. Roberts, S. Norval, S. Patterson, B. J. Foth et al., Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania, PLoS Pathog, vol.12, issue.11, 2016.

S. Patterson, S. Wyllie, L. Stojanovski, M. R. Perry, F. R. Simeons et al., The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis, Antimicrob. Agents Chemother, vol.2013, issue.10, pp.4699-4706

B. S. Hall and S. R. Wilkinson, Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation, Antimicrob. Agents Chemother, vol.56, issue.1, pp.115-123, 2012.

B. S. Hall, C. Bot, and S. R. Wilkinson, Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites, J. Biol. Chem, issue.15, pp.13088-13095, 2011.

C. Castera-ducros, L. Paloque, P. Verhaeghe, M. Casanova, C. Cantelli et al., Targeting the human parasite Leishmania donovani: Discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series, Bioorg. Med. Chem, vol.21, issue.22, pp.7155-7164, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01460446

C. Fersing, C. Boudot, J. Pedron, S. Hutter, N. Primas et al., Vanelle, P. 8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases, Eur. J. Med. Chem, vol.157, pp.115-126, 2018.

P. Verhaeghe, A. Dumetre, C. Castera-ducros, S. Hutter, M. Laget et al., Azas, N. 4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum, Bioorg. Med. Chem. Lett, issue.19, pp.6003-6006, 2011.

C. Kieffer, A. Cohen, P. Verhaeghe, S. Hutter, C. Castera-ducros et al., Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series, Eur. J. Med. Chem, vol.92, pp.282-294, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01460569

W. Raether and H. Seidenath, The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica, Ann. Trop. Med. Parasitol, vol.77, issue.1, pp.13-26, 1983.

D. Pal, S. Banerjee, J. Cui, A. Schwartz, S. K. Ghosh et al., Entamoeba and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases), Antimicrob. Agents Chemother, vol.53, issue.2, pp.458-464, 2009.

J. Mccann, N. E. Spingarn, J. Kobori, and B. N. Ames, Detection of carcinogens as mutagens: bacterial tester strains with R factor plasmids, Proc. Natl. Acad. Sci. U. S. A, vol.72, issue.3, pp.979-983, 1975.

J. S. Walsh, R. Wang, E. Bagan, C. C. Wang, P. Wislocki et al., Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles, J. Med. Chem, vol.30, issue.1, pp.150-156, 1987.

J. L. Blumer, A. Friedman, L. W. Meyer, E. Fairchild, L. T. Webster et al., Relative importance of bacterial and mammalian nitroreductases for niridazole mutagenesis, Cancer Res, vol.40, issue.12, pp.4599-4605, 1980.

Y. Yanto, M. Hall, and A. S. Bommarius, Nitroreductase from Salmonella typhimurium: characterization and catalytic activity, Org. Biomol. Chem, vol.8, issue.8, pp.1826-1832, 2010.

D. Tweats, B. Bourdin-trunz, and E. Torreele, Genotoxicity profile of fexinidazole, a drug candidate in clinical development for human African trypanomiasis (sleeping sickness), Mutagenesis, vol.2012, issue.5, pp.523-532

K. Katsuno, J. N. Burrows, K. Duncan, R. Hooft-van-huijsduijnen, T. Kaneko et al., Hit and lead criteria in drug discovery for infectious diseases of the developing world, Nat. Rev. Drug Discovery, vol.14, issue.11, pp.751-758, 2015.

D. A. Smith, L. Di, and E. H. Kerns, The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery, Nat. Rev. Drug Discovery, vol.2010, issue.12, pp.929-939